PEPG Crashes as Duchenne Drug Fails, Investors Sue

PepGen Inc. promised investors a breakthrough cure for Duchenne muscular dystrophy.  But when the science wasn’t there, patients and shareholders were left heartbroken.  The stock crashed, and now investors are suing.

In twenty twenty-four, PepGen hyped its PGN-EDO51 drug, boasting it would deliver amazing results and a clear path to FDA approval.  But they hid dismal lab results, serious safety risks, and FDA scrutiny, leaving the stock price propped up on false promises.

The truth hit hard in late 2024 and 2025. Dismal trial data and major safety issues prompted FDA red flags.  PepGen had to ditch the program and investors dumped their shares. The stock plunged 32% in a day and kept tanking, costing hundreds of millions.

Now, more shareholders are joining the lawsuit.